AAAmitha Ananth

Amitha Ananth

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amitha Ananth has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gene therapy for metachromatic leukodystrophy: Compassionate use experience with atidarsagene autotemcel in the United States

    by Paul Orchard, Amitha Ananth, Jennifer Braun, Julie B. Eisengart, Ashish O. Gupta, Kristen Lee, Troy C. Lund, Saima Kayani, Nishitha R. Pillai, Ami J. Shah, et al.

    Background: Atidarsagene autotemcel (arsa-cel) is an ex vivo, lentiviral, autologous, hematopoietic stem cell–based gene therapy approved for the treatment of children with early-onset metachromatic leukodystrophy (MLD). This case series describes early experience with arsa-cel treatment in the United States and provides information on variable paths to identification and diagnosis of patients with MLD. Methods: Prior to approval by the US Food and Drug Administration, five patients classified as having early-onset MLD were treated with arsa-cel on a single-patient compassionate use basis at the University of Minnesota. Results: Two patients with presymptomatic late-infantile MLD were identified because of older siblings with MLD. Three patients were identified because of gallbladder disease, cranial neuropathy, or motor delays. All patients achieved hematologic recovery, and leukocyte arylsulfatase A activity increased to normal or above-normal levels within 30 days posttreatment. After 24 to 48 months (median, 36 months) of follow-up, the three patients who were presymptomatic at the time of treatment were independently ambulatory at last assessment. The two patients with early symptomatic early-juvenile MLD experienced cognitive and neurologic deterioration. Conclusion: This case series provides examples of the variety of clinical presentations in patients with MLD and emphasizes the importance of prompt diagnosis and referral of patients with early-onset MLD to provide the best opportunity to achieve optimal outcomes.

  • Emerging Topics in Neurogenomics: Summary From Inaugural Child Neurology Society Genetics Summit

    by Kuntal Sen, Rachel Gottlieb-Smith, Srika Amin, Amitha Ananth, Victoria Bartlett, Nancy Bass, Dylan Brock, Elaine Conrad, Sophia Ceulemans, Laura Davids, et al.


  • Open Access

    Leisure-Time Physical Activity Interventions for Individuals with Rett Syndrome: Scoping Review (Preprint)

    by Christen Mendonca, James Rimmer, Ashley Wright, Raven Young, Amitha Ananth, Byron Lai

    Background: While half of individuals with Rett syndrome (RTT) are older than 50 years, research shows that they have low levels of physical activity, especially for those of advanced age and poor ambulation. Despite this evidence, recent studies underscore the potential of leisure-time physical activity interventions to improve health outcomes and quality of life for individuals with RTT. Objective: This scoping review aimed to summarize the state of the science regarding physical activity interventions for individuals with RTT and their families across the life span; map the extent, range, and nature of research activity in telehealth; and describe outcomes targeted by interventions with a focus on health-related fitness. Methods: Systematic searches were performed in the MEDLINE, Scopus, Google Scholar, and CINAHL Plus databases. The data charted from eligible studies included specific details about the participants, study design, setting, intervention characteristics, outcomes, and relevant key findings. Inclusion criteria were (1) original, peer-reviewed research; (2) full-text articles in English; (3) studies reporting a leisure-time physical activity intervention; and (4) a sample of individuals with RTT and/or caregivers. Results: A total of 23 studies enrolled 200 participants in total (mean age 13, SD 7, range 2-48 years). Participants were all female individuals, and studies included mostly those who were ambulatory. RTT severity was reported in less than half (9/23, 39%) of the studies; however, participants with mild to severe scores were represented. Most of the studies (20/23, 87%) used a case study design or single-group repeated measures, and only 13% (3/23) were randomized trials. The focus was primarily on gross motor function, walking ability, and physical activity outcomes. In total, 39% (9/23) of the interventions implemented telehealth into their design, primarily using remote video calls between a physical therapist and the participants’ parents. Conclusions: The findings of this review provide a foundation for designing evidence-based, scalable physical activity programs tailored to the unique needs of individuals with RTT. The integration of telehealth strategies offers a promising avenue for enhancing accessibility and caregiver engagement.

  • Open Access

    Leisure-time physical activity interventions for health promotion in individuals with Rett syndrome: A scoping review (Preprint)

    by Christen Mendonca, James Rimmer, Ashley Wright, Raven Young, Amitha Ananth, Byron Lai

    BACKGROUND While half of individuals with Rett syndrome exceed 50 years of age, research shows that they have low levels of physical activity, especially for those of advanced age and poor ambulation. Despite this evidence, recent studies underscore the potential of leisure-time physical activity interventions to improve health outcomes and quality of life for individuals with Rett syndrome. OBJECTIVE This scoping review aimed to summarize the state of the science regarding physical interventions for individuals with Rett syndrome and their families across the lifespan, map the extent, range and nature of research activity in telehealth, and to describe outcomes targeted by interventions with a focus on health-related fitness. METHODS Systematic searches were performed within MEDLINE, SCOPUS, Google Scholar and CINAHL Plus. The data charted from eligible studies included specific details about the participants, study design, setting, intervention characteristics, outcomes, and relevant key findings. Inclusion criteria: (1) original, peer-reviewed research, (2) full text articles in English, (3) study reported a leisure-time physical activity intervention, (4) had a sample of individuals with RTT and or a caregiver. RESULTS Twenty-three studies enrolled a total of 200 participants (mean age of 13±7, range 2 to 48 years of age). Participants were all females and studies included mostly ambulatory individuals. Rett syndrome severity was reported in less than half of the studies; however, the participants with mild to severe scores were represented. Most of the studies used a case study design or single group repeated measures and only three randomized trials were identified. The focus was primarily on gross motor function, walking ability, and physical activity outcomes. Nine interventions implemented telehealth into their design primarily using remote video call between a physical therapist and the participant’s parent. CONCLUSIONS The findings of this review provide a foundation for designing evidence-based, scalable physical activity programs tailored to the unique needs of individuals with RTT. The integration of telehealth strategies offers a promising avenue for enhancing accessibility and caregiver engagement.

  • Medical Biases and Misconceptions Impact Diagnoses in Males With Loss of Function MECP2 Variants

    by Talia Thompson, Dennis Gurfinkel, Lori Silveira, Natalia Klamut, Kate Ferdinandsen, Cary Fu, Amitha L. Ananth, Jane B. Lane, Eric D. Marsh, Jeffrey L. Neul, et al.

    Rett syndrome (RTT) is a rare neurodevelopmental disorder typically caused by loss‐of‐function variants in the transcriptional regulator methyl‐CpG binding protein‐2 (MECP2) gene. These variants were historically believed to be incompatible with life in males; however, recent advances in genetic testing have revealed significant clinical heterogeneity. The current study aimed to improve our understanding of diagnostic experiences in males with confirmed pathogenic alteration of MECP2. An international sample of caregivers completed a survey of diagnostic experiences (N = 47) and phenomenological interviews (n = 32). Median [interquartile range; IQR] age of genetic diagnosis was 3 years [1.08, 6.75]. Multivariate analysis showed that for every year increase in year of birth, age of diagnosis (in years) decreased by 0.31. Qualitative findings demonstrate that medical biases and widespread misconceptions contribute to delays in accurate clinical diagnosis, which negatively impacts child health and family functioning. As genetic testing becomes more widely available, age of genetic diagnosis is decreasing, resulting in more providers and families with unexpected results and a notable lack of male‐specific anticipatory guidance and clinical recommendations. Diagnostic providers must increase their awareness of males with confirmed pathogenic alterations of MECP2 and be prepared to deliver the diagnosis with empathy and accurate, up‐to‐date information on prognosis and treatment options.


  • Open Access

    International workshop: what is needed to ensure outcome measures for Rett syndrome are fit-for-purpose for clinical trials? June 7, 2023, Nashville, USA

    by Jenny Downs, Dominique C. Pichard, Walter E. Kaufmann, Joseph P. Horrigan, Melissa Raspa, Gillian Townend, Eric D. Marsh, Helen Leonard, Kathleen Motil, Andrew C. Dietz, et al.

    Introduction: The clinical, research and advocacy communities for Rett syndrome are striving to achieve clinical trial readiness, including having fit-for-purpose clinical outcome assessments. This study aimed to (1) describe psychometric properties of clinical outcome assessment for Rett syndrome and (2) identify what is needed to ensure that fit-for-purpose clinical outcome assessments are available for clinical trials. Methods: Clinical outcome assessments for the top 10 priority domains identified in the Voice of the Patient Report for Rett syndrome were compiled and available psychometric data were extracted. The clinical outcome assessments measured clinical severity, functional abilities, comorbidities and quality of life, and electrophysiological biomarkers. An international and multidisciplinary panel of 29 experts with clinical, research, psychometric, biostatistical, industry and lived experience was identified through International Rett Syndrome Foundation networks, to discuss validation of the clinical outcome assessments, gaps and next steps, during a workshop and in a follow-up questionnaire. The identified gaps and limitations were coded using inductive content analysis. Results: Variable validation profiles across 26 clinical outcome assessments of clinical severity, functional abilities, and comorbidities were discussed. Reliability, validity, and responsiveness profiles were mostly incomplete; there were limited content validation data, particularly parent-informed relevance, comprehensiveness and comprehensibility of items; and no data on meaningful change or cross-cultural validity. The panel identified needs for standardised administration protocols and systematic validation programmes. Conclusion: A pipeline of collaborative clinical outcome assessment development and validation research in Rett syndrome can now be designed, aiming to have fit-for-purpose measures that can evaluate meaningful change, to serve future clinical trials and clinical practice.


  • MECP2 Variants in Males: More Common than Previously Appreciated

    by Amitha Ananth, Cary Fu, Jeffrey L. Neul, Tim Benke, Eric Marsh, Bernhard Suter, Kathleen Ferdinandsen, Steven A. Skinner, Fran Annese, Alan K. Percy